Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Polarized cellular mechanoresponse system for maintaining radial size in developing epithelial tubes.

Hirashima T, Adachi T.

Development. 2019 Oct 16. pii: dev.181206. doi: 10.1242/dev.181206. [Epub ahead of print]

2.

Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer.

Nasu S, Okamoto N, Suzuki H, Shiroyama T, Tanaka A, Samejima Y, Kanai T, Noda Y, Morita S, Morishita N, Ueda K, Kawahara K, Hirashima T.

Anticancer Res. 2019 Oct;39(10):5683-5688. doi: 10.21873/anticanres.13766.

PMID:
31570467
3.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T.

Ann Oncol. 2019 Sep 25. pii: mdz399. doi: 10.1093/annonc/mdz399. [Epub ahead of print]

PMID:
31553438
4.

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D.

Invest New Drugs. 2019 Aug 7. doi: 10.1007/s10637-019-00843-y. [Epub ahead of print]

PMID:
31392549
5.

Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.

Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.

Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.

6.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

7.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T.

Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544.

PMID:
31262922
8.

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma.

Masuhiro K, Koh G, Takata S, Nasu S, Takada H, Morita S, Tanaka A, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Kawasumi H, Konishi C, Hirashima T.

Respir Med Case Rep. 2019 May 26;28:100862. doi: 10.1016/j.rmcr.2019.100862. eCollection 2019.

9.

Multimodal Imaging for Differential Diagnosis of Bietti Crystalline Dystrophy.

Oishi A, Oishi M, Miyata M, Hirashima T, Hasegawa T, Numa S, Tsujikawa A.

Ophthalmol Retina. 2018 Oct;2(10):1071-1077. doi: 10.1016/j.oret.2018.02.012. Epub 2018 Apr 4.

PMID:
31047497
10.

Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease.

Nasu S, Suzuki H, Moriizumi K, Hara Y, Tanaka S, Takada H, Morita S, Tanaka A, Shiroyama T, Morishita N, Okamoto N, Hirashima T.

J Thorac Dis. 2019 Feb;11(2):514-520. doi: 10.21037/jtd.2019.01.26.

11.

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.

Yokoi T, Minami S, Shiroyama T, Koba T, Torii Y, Sugimoto H, Niki M, Mori M, Morimura O, Hirashima T, Komuta K, Kijima T.

Intern Med. 2019 May 15;58(10):1405-1410. doi: 10.2169/internalmedicine.1172-18. Epub 2019 Feb 1.

12.

Novel roles of Drosophila FUS and Aub responsible for piRNA biogenesis in neuronal disorders.

Wakisaka KT, Tanaka R, Hirashima T, Muraoka Y, Azuma Y, Yoshida H, Tokuda T, Asada S, Suda K, Ichiyanagi K, Ohno S, Itoh M, Yamaguchi M.

Brain Res. 2019 Apr 1;1708:207-219. doi: 10.1016/j.brainres.2018.12.028. Epub 2018 Dec 19.

PMID:
30578769
13.

Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study.

Hirashima T, Tamura Y, Han Y, Hashimoto S, Tanaka A, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Akada S, Fujishima M, Kadota Y, Sakata K, Nishitani A, Miyazaki S, Nagai T.

BMC Cancer. 2018 Oct 12;18(1):975. doi: 10.1186/s12885-018-4889-1.

14.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
15.

Dynamic MAPK/ERK Activity Sustains Nephron Progenitors through Niche Regulation and Primes Precursors for Differentiation.

Ihermann-Hella A, Hirashima T, Kupari J, Kurtzeborn K, Li H, Kwon HN, Cebrian C, Soofi A, Dapkunas A, Miinalainen I, Dressler GR, Matsuda M, Kuure S.

Stem Cell Reports. 2018 Oct 9;11(4):912-928. doi: 10.1016/j.stemcr.2018.08.012. Epub 2018 Sep 13.

16.

The ABD on the nascent polypeptide and PH domain are required for the precise Anillin localization in Drosophila syncytial blastoderm.

Hirashima T, Tanaka R, Yamaguchi M, Yoshida H.

Sci Rep. 2018 Aug 27;8(1):12910. doi: 10.1038/s41598-018-31106-0.

17.

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.

Nasu S, Shiroyama T, Morita S, Takata S, Takada H, Masuhiro K, Tanaka A, Morishita N, Suzuki H, Okamoto N, Hirashima T.

Intern Med. 2018 Dec 15;57(24):3643-3645. doi: 10.2169/internalmedicine.0923-18. Epub 2018 Aug 24.

18.

Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study.

Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, Oh H, Matsumoto Y, Uenishi M, Kurimoto Y.

Br J Ophthalmol. 2019 Jun;103(6):844-848. doi: 10.1136/bjophthalmol-2018-312419. Epub 2018 Aug 4.

PMID:
30077969
19.

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T.

Anticancer Res. 2018 Aug;38(8):4723-4729. doi: 10.21873/anticanres.12779.

PMID:
30061241
20.

Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.

Takata S, Koh G, Han Y, Yoshida H, Shiroyama T, Takada H, Masuhiro K, Nasu S, Morita S, Tanaka A, Hashimoto S, Uriu K, Suzuki H, Tamura Y, Okamoto N, Nagai T, Hirashima T.

J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25.

21.

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.

Nakahama K, Tamiya A, Isa SI, Taniguchi Y, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S.

In Vivo. 2018 Jul-Aug;32(4):887-891. doi: 10.21873/invivo.11324.

22.

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis.

Gocho N, Aoki E, Okada C, Hirashima T.

Intern Med. 2018 Nov 1;57(21):3117-3122. doi: 10.2169/internalmedicine.0639-17. Epub 2018 Jun 6.

23.

Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.

Masuhiro K, Shiroyama T, Suzuki H, Takata SO, Nasu S, Takada H, Morita S, Tanaka A, Morishita N, Okamoto N, Hirashima T.

Anticancer Res. 2018 Jun;38(6):3567-3571. doi: 10.21873/anticanres.12629.

PMID:
29848711
24.

Transformation to small cell lung cancer after first-line afatinib treatment.

Shiroyama T, Nasu S, Tanaka A, Takata S, Masuhiro K, Takada H, Morita S, Morishita N, Suzuki H, Okamoto N, Kawahara K, Hirashima T.

Respir Med Case Rep. 2018 Mar 1;23:188-190. doi: 10.1016/j.rmcr.2018.02.011. eCollection 2018.

25.

[Endoscopy-Assisted Partial Duodenal Resection for Duodenal Adenoma in a Patient with Familial Adenomatous Polyposis].

Hirashima T, Ohnuma S, Karasawa H, Watanabe K, Imoto H, Aoki T, Kudoh K, Tanaka N, Nagao M, Musha H, Motoi F, Kamei T, Naitoh T, Unno M.

Gan To Kagaku Ryoho. 2018 Mar;45(3):518-520. Japanese.

PMID:
29650924
26.

Metastatic colonic and gastric polyps from breast cancer resembling hyperplastic polyps.

Horimoto Y, Hirashima T, Arakawa A, Miura H, Saito M.

Surg Case Rep. 2018 Mar 23;4(1):23. doi: 10.1186/s40792-018-0433-4.

27.

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Tamiya M, Suzuki H, Shiroyama T, Tanaka A, Morishita N, Okamoto N, Sakai K, Shigeoka H, Kawahara K, Hirashima T.

Invest New Drugs. 2018 Aug;36(4):696-701. doi: 10.1007/s10637-018-0581-1. Epub 2018 Mar 14.

PMID:
29536229
28.

Skin Rash Can Be a Useful Marker for Afatinib Efficacy.

Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T.

Anticancer Res. 2018 Mar;38(3):1783-1788.

PMID:
29491117
29.

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.

Satoh S, Shiroyama T, Tamiya M, Nasu S, Tanaka A, Morita S, Morishita N, Suzuki H, Okamoto N, Hirashima T.

Respir Med Case Rep. 2017 Dec 11;23:68-70. doi: 10.1016/j.rmcr.2017.12.005. eCollection 2018.

30.

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.

Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Suzuki H, Hirashima T, Atagi S, Imamura F.

PLoS One. 2018 Feb 22;13(2):e0192227. doi: 10.1371/journal.pone.0192227. eCollection 2018.

31.

Evolution of the Phosphatidylcholine Biosynthesis Pathways in Green Algae: Combinatorial Diversity of Methyltransferases.

Hirashima T, Toyoshima M, Moriyama T, Sato N.

J Mol Evol. 2018 Jan;86(1):68-76. doi: 10.1007/s00239-017-9826-4. Epub 2018 Jan 12.

PMID:
29330556
32.

Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash.

Usui N, Kondo Y, Ryota N, Suzuki H, Okamoto N, Sando M, Tani E, Hamaguchi M, Tanaka A, Tamiya M, Shiroyama T, Morishita N, Tanaka E, Hirashima T.

Eur J Hosp Pharm. 2017 Sep;24(5):283-285. doi: 10.1136/ejhpharm-2016-000957. Epub 2016 Aug 3.

33.

Choriocapillaris flow deficit in Bietti crystalline dystrophy detected using optical coherence tomography angiography.

Miyata M, Oishi A, Hasegawa T, Ishihara K, Oishi M, Ogino K, Sugahara M, Hirashima T, Hata M, Yoshikawa M, Tsujikawa A.

Br J Ophthalmol. 2018 Sep;102(9):1208-1212. doi: 10.1136/bjophthalmol-2017-311313. Epub 2017 Dec 2.

PMID:
29197825
34.

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T.

Cancer Med. 2018 Jan;7(1):13-20. doi: 10.1002/cam4.1234. Epub 2017 Nov 18.

35.

Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.

Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, Atagi S, Imamura F.

Clin Lung Cancer. 2018 Mar;19(2):e171-e176. doi: 10.1016/j.cllc.2017.09.002. Epub 2017 Oct 13.

PMID:
29133121
36.

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.

Tamiya M, Tamiya A, Shiroyama T, Takeoka S, Naito Y, Omachi N, Kimura Y, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T.

Invest New Drugs. 2018 Aug;36(4):608-614. doi: 10.1007/s10637-017-0527-z. Epub 2017 Nov 4.

PMID:
29101518
37.

Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.

Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K.

Am J Clin Oncol. 2018 Oct;41(10):967-971. doi: 10.1097/COC.0000000000000412.

PMID:
29045265
38.

The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.

Nakahama K, Isa SI, Tamiya A, Taniguchi Y, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S.

Anticancer Res. 2017 Oct;37(10):5885-5891. Erratum in: Anticancer Res. 2017 Nov;37(11):6495. Anticancer Res. 2017 Dec;37(12 ):7105. Anticancer Res. 2017 Dec;37(12 ):7105. Anticancer Res. 2017 Dec;37(12 ):7105. Anticancer Res. 2017 Dec;37(12 ):7105.

PMID:
28982916
39.

Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.

Taniguchi Y, Tamiya A, Isa SI, Nakahama K, Okishio K, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S.

Anticancer Res. 2017 Oct;37(10):5857-5862.

PMID:
28982912
40.

Influences of 27-Gauge Vitrectomy on Corneal Topographic Conditions.

Hirashima T, Utsumi T, Hirose M, Oh H.

J Ophthalmol. 2017;2017:8320909. doi: 10.1155/2017/8320909. Epub 2017 Aug 27.

41.

In vitro tubulogenesis of Madin-Darby canine kidney (MDCK) spheroids occurs depending on constituent cell number and scaffold gel concentration.

Hirashima T, Hoshuyama M, Adachi T.

J Theor Biol. 2017 Dec 21;435:110-115. doi: 10.1016/j.jtbi.2017.09.009. Epub 2017 Sep 15.

PMID:
28923372
42.

Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.

Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Inoue T, Okishio K, Nishino K, Kumagai T, Suzuki H, Hirashima T, Imamura F, Atagi S.

Anticancer Res. 2017 Sep;37(9):5199-5205.

PMID:
28870955
43.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T.

ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.

44.

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis.

Naito Y, Tamiya A, Tamiya M, Kimura Y, Hamaguchi M, Saijo N, Kanazu M, Tokura S, Shiroyama T, Morisita N, Omachi N, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S.

Medicine (Baltimore). 2017 Sep;96(35):e7884. doi: 10.1097/MD.0000000000007884.

45.

Choroidal Vasculature in Bietti Crystalline Dystrophy With CYP4V2 Mutations and in Retinitis Pigmentosa With EYS Mutations.

Hirashima T, Miyata M, Ishihara K, Hasegawa T, Sugahara M, Ogino K, Yoshikawa M, Hata M, Kuroda Y, Muraoka Y, Ooto S, Yoshimura N.

Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):3871-3878. doi: 10.1167/iovs.17-21515.

PMID:
28763560
46.

Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.

Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, Takeuchi N, Isa SI, Omachi N, Okamoto N, Suzuki H, Okishio K, Iwazaki A, Imai K, Hirashima T, Atagi S.

Anticancer Res. 2017 Aug;37(8):4177-4182.

PMID:
28739703
47.

Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.

Shiroyama T, Tamiya M, Minami S, Takata S, Masuhiro K, Futami-Nishijima Y, Uenami T, Mori M, Koba T, Matsuki T, Takimoto T, Suzuki H, Okamoto N, Komuta K, Hirashima T, Kumanogoh A, Kijima T.

Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467. doi: 10.1007/s00280-017-3385-7. Epub 2017 Jul 7.

PMID:
28688052
48.

Cellular Potts modeling of complex multicellular behaviors in tissue morphogenesis.

Hirashima T, Rens EG, Merks RMH.

Dev Growth Differ. 2017 Jun;59(5):329-339. doi: 10.1111/dgd.12358. Epub 2017 Jun 8. Review.

PMID:
28593653
49.

Characterization of phosphoethanolamine-N-methyltransferases in green algae.

Hirashima T, Toyoshima M, Moriyama T, Nakamura Y, Sato N.

Biochem Biophys Res Commun. 2017 Jun 17;488(1):141-146. doi: 10.1016/j.bbrc.2017.05.026. Epub 2017 May 5.

PMID:
28483522
50.

Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.

Nishijima-Futami Y, Minami S, Futami S, Koba T, Higashiguchi M, Tamiya M, Suzuki H, Hirashima T, Komuta K, Kijima T.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1215-1220. doi: 10.1007/s00280-017-3321-x. Epub 2017 Apr 28.

PMID:
28455584

Supplemental Content

Loading ...
Support Center